Tvardi Therapeutics
$1.9100
94
+$0.06+3.24% Friday 20:00
-$0.03-1.57%Friday 23:30After hours
Statistics
Day High
1.92
Day Low
1.89
52W High
43.65
52W Low
1.5
Volume
4,665
Avg. Volume
-
Mkt Cap
25.48M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
12NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-7.08
-4.9
-2.72
-0.54
Expected EPS
-0.541963
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-18.21MNet Income
Analyst Ratings
6.00Average Price Target
The highest estimate is 10.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy 60%
Hold 20%
Sell 20%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow TVRD. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Johnson & Johnson
JNJ
Mkt Cap645.95B
Abbvie
ABBV
Mkt Cap451.46B
Pfizer
PFE
Mkt Cap159.36B
Novartis
NVS
Mkt Cap292.35B
Merck
MRK
Mkt Cap366B
Gilead Sciences
GILD
Mkt Cap180.64B
Alkermes
ALKS
Mkt Cap7.95B
About
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Show more...
CEO
Imran Alibhai
Employees
12
Country
United States
ISIN
US1407553072
WKN
000A414VY
Listings
0 Comments
Share your thoughts
FAQ
What is Tvardi Therapeutics stock price today?▼
The current price of TVRD is $1.91 USD — it has increased by +3.24% in the past 24 hours. Watch Tvardi Therapeutics stock price performance more closely on the chart.
What is Tvardi Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Tvardi Therapeutics stocks are traded under the ticker TVRD.
Is Tvardi Therapeutics stock price growing?▼
TVRD stock has risen by +4.95% compared to the previous week, the month change is a -4.5% fall, over the last year Tvardi Therapeutics has showed a -93.86% decrease.
What is Tvardi Therapeutics market cap?▼
Today Tvardi Therapeutics has the market capitalization of 25.48M
When is the next Tvardi Therapeutics earnings date?▼
Tvardi Therapeutics is going to release the next earnings report on November 12, 2026.
What were Tvardi Therapeutics earnings last quarter?▼
TVRD earnings for the last quarter are -0.69 USD per share, whereas the estimation was -0.7 USD resulting in a +2.05% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tvardi Therapeutics revenue for the last year?▼
Tvardi Therapeutics revenue for the last year amounts to 0 USD.
What is Tvardi Therapeutics net income for the last year?▼
TVRD net income for the last year is -18.21M USD.
How many employees does Tvardi Therapeutics have?▼
As of September 05, 2026, the company has 12 employees.
In which sector is Tvardi Therapeutics located?▼
Tvardi Therapeutics operates in the Health & Wellness sector.
When did Tvardi Therapeutics complete a stock split?▼
The last stock split for Tvardi Therapeutics was on April 16, 2025 with a ratio of 1:3.
Where is Tvardi Therapeutics headquartered?▼
Tvardi Therapeutics is headquartered in SUGAR LAND, United States.